MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584654 | Name: M 16209

Description:

WARNING: This product is for research use only, not for human or veterinary use.

M 16209 has been found to be an antidiabetic agent due to amelioration of insulin resistance in peripheral tissues.

Chemical Structure

M 16209
M 16209
CAS#128851-36-5

Theoretical Analysis

MedKoo Cat#: 584654

Name: M 16209

CAS#: 128851-36-5

Chemical Formula: C11H7BrN2O5S

Exact Mass: 357.9259

Molecular Weight: 359.15

Elemental Analysis: C, 36.79; H, 1.96; Br, 22.25; N, 7.80; O, 22.27; S, 8.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
M 16209; M-16209; M16209
IUPAC/Chemical Name
2,4-Imidazolidinedione, 1-((3-bromo-2-benzofuranyl)sulfonyl)-
InChi Key
ZJSUDHQFSBHLDV-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H7BrN2O5S/c12-9-6-3-1-2-4-7(6)19-10(9)20(17,18)14-5-8(15)13-11(14)16/h1-4H,5H2,(H,13,15,16)
SMILES Code
O=C1NC(CN1S(=O)(C2=C(Br)C3=CC=CC=C3O2)=O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 359.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Murakami N, Ohta M, Kato K, Nakayama K, Mizota M, Miwa I, Okuda J. Effects of 1-(3-bromobenzofuran-2-ylsulfonyl)hydantoin on human aldose reductase examined by a new application of HPLC system for measuring tissue polyol. Arzneimittelforschung. 1997 Nov;47(11):1222-5. PubMed PMID: 9428978. 2: Ohta M, Murakami N, Kato K, Mizota M, Miwa I, Okuda J, Yoshimasa Y, Kuzuya H, Nakao K, Imura H. Effects of M16209, a new antihyperglycemic agent, on insulin sensitivity in vivo: euglycemic clamp studies in rats. Metabolism. 1996 Sep;45(9):1095-100. PubMed PMID: 8781296. 3: Kato K, Nakayama K, Mizota M, Miwa I, Okuda J. Properties of novel aldose reductase inhibitors, M16209 and M16287, in comparison with known inhibitors, ONO-2235 and sorbinil. Chem Pharm Bull (Tokyo). 1991 Jun;39(6):1540-5. PubMed PMID: 1934175. 4: Kato K, Nakayama K, Ohta M, Murakami N, Murakami K, Mizota M, Miwa I, Okuda J. Effects of novel hydantoin derivatives with aldose reductase inhibiting activity on galactose-induced cataract in rats. Jpn J Pharmacol. 1990 Dec;54(4):355-64. PubMed PMID: 2128352. 5: Nakayama K, Murakami N, Ohta M, Kato K, Notsu T, Mizota M, Miwa I, Okuda J. Effects of M16209 on insulin secretion in isolated, perfused pancreases of normal and diabetic rats. Eur J Pharmacol. 1995 Mar 24;276(1-2):85-91. PubMed PMID: 7781699. 6: Kato K, Nakayama K, Ohta M, Murakami N, Murakami K, Mizota M, Miwa I, Okuda J. Effects of novel aldose reductase inhibitors, M16209 and M16287, on streptozotocin-induced diabetic neuropathy in rats. Eur J Pharmacol. 1991 Feb 7;193(2):185-91. PubMed PMID: 1828768. 7: Murakami N, Inoue G, Okamoto M, Yoshimasa Y, Kohno S, Hayashi T, Kato K, Kuzuya H, Nakao K. Antihyperglycemic mechanism of M16209, an antidiabetic agent, in 3T3-L1 adipocytes. Life Sci. 1997;60(20):1821-31. PubMed PMID: 9150422. 8: Nakayama K, Murakami N, Ohta M, Kato K, Ida K, Mizota M, Miwa I, Okuda J. Antihyperglycemic effects of M16209, a novel aldose reductase inhibitor, in normal and diabetic rats. Eur J Pharmacol. 1995 Mar 24;276(1-2):77-83. PubMed PMID: 7781698. 9: Murakami N, Ohta M, Hashimoto K, Kato K, Mizota M, Miwa I, Okuda J, Inoue G, Kuzuya H, Nakao K, Imura H. Amelioration of insulin resistance in genetically obese rodents by M16209, a new antidiabetic agent. Eur J Pharmacol. 1996 May 23;304(1-3):129-34. PubMed PMID: 8813594. 10: Hashimoto K, Murakami N, Ohta M, Kato K, Mizota M, Miwa I, Okuda J. Acceleration of glycolysis in erythrocytes by the antidiabetic agent M16209. Biol Pharm Bull. 1996 Jun;19(6):809-13. PubMed PMID: 8799477.